PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 180 participants.
Also called NCT07243119
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose diagnostic
- Phase
- Phase 4
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT07243119
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07243119. Randomized; quadruple masking; primary purpose diagnostic. Start 2025-12-08 (actual); primary completion 2029-04-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure
- Acronym
- PRIMA-HF
- Condition
- Heart Failure and Reduced Ejection Fraction
- Condition
- Heart Failure
- Intervention (Diagnostic test)
- HAI-HF: Adenosine Stress [¹⁵O]H₂O PET Imaging
- Intervention (Drug)
- Two different doses of adenosine
- Lead sponsor
- Gødstrup Hospital
Record details
- Record id
cardio:ct-nct07243119- Content hash
430b0f79cd317614f1a4ba8959d12d7b92d9098aa81d29ca307117893de81bac